Mascola JR - Search Results

1

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.

Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group. Crowell TA, et al. Among authors: mascola jr. Lancet HIV. 2019 May;6(5):e297-e306. doi: 10.1016/S2352-3018(19)30053-0. Epub 2019 Apr 15. Lancet HIV. 2019. PMID: 31000477 Free PMC article. Clinical Trial.

2

Multiple introductions of HIV-1 subtype E into the western hemisphere.

Artenstein AW, Coppola J, Brown AE, Carr JK, Sanders-Buell E, Galbarini E, Mascola JR, VanCott TC, Schonbrood P, McCutchan FE, et al. Artenstein AW, et al. Among authors: mascola jr. Lancet. 1995 Nov 4;346(8984):1197-8. doi: 10.1016/s0140-6736(95)92900-2. Lancet. 1995. PMID: 7475660

3

Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans.

Artenstein AW, VanCott TC, Mascola JR, Carr JK, Hegerich PA, Gaywee J, Sanders-Buell E, Robb ML, Dayhoff DE, Thitivichianlert S, et al. Artenstein AW, et al. Among authors: mascola jr. J Infect Dis. 1995 Apr;171(4):805-10. doi: 10.1093/infdis/171.4.805. J Infect Dis. 1995. PMID: 7706806

4

The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression.

Michael NL, Chang G, Louie LG, Mascola JR, Dondero D, Birx DL, Sheppard HW. Michael NL, et al. Among authors: mascola jr. Nat Med. 1997 Mar;3(3):338-40. doi: 10.1038/nm0397-338. Nat Med. 1997. PMID: 9055864

5

Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection--evidence for highly susceptible human hosts.

Michael NL, Brown AE, Voigt RF, Frankel SS, Mascola JR, Brothers KS, Louder M, Birx DL, Cassol SA. Michael NL, et al. Among authors: mascola jr. J Infect Dis. 1997 Jun;175(6):1352-9. doi: 10.1086/516467. J Infect Dis. 1997. PMID: 9180174

6

Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

Mascola JR, Louder MK, VanCott TC, Sapan CV, Lambert JS, Muenz LR, Bunow B, Birx DL, Robb ML. Mascola JR, et al. J Virol. 1997 Oct;71(10):7198-206. doi: 10.1128/JVI.71.10.7198-7206.1997. J Virol. 1997. PMID: 9311792 Free PMC article.

7

Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection.

Loomis-Price LD, Cox JH, Mascola JR, VanCott TC, Michael NL, Fouts TR, Redfield RR, Robb ML, Wahren B, Sheppard HW, Birx DL. Loomis-Price LD, et al. Among authors: mascola jr. J Infect Dis. 1998 Nov;178(5):1306-16. doi: 10.1086/314436. J Infect Dis. 1998. PMID: 9780250

8

Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.

Frankel SS, Steinman RM, Michael NL, Kim SR, Bhardwaj N, Pope M, Louder MK, Ehrenberg PK, Parren PW, Burton DR, Katinger H, VanCott TC, Robb ML, Birx DL, Mascola JR. Frankel SS, et al. Among authors: mascola jr. J Virol. 1998 Dec;72(12):9788-94. doi: 10.1128/JVI.72.12.9788-9794.1998. J Virol. 1998. PMID: 9811714 Free PMC article.

9

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL. Mascola JR, et al. J Virol. 1999 May;73(5):4009-18. doi: 10.1128/JVI.73.5.4009-4018.1999. J Virol. 1999. PMID: 10196297 Free PMC article.

10

Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.

VanCott TC, Mascola JR, Loomis-Price LD, Sinangil F, Zitomersky N, McNeil J, Robb ML, Birx DL, Barnett S. VanCott TC, et al. Among authors: mascola jr. J Virol. 1999 Jun;73(6):4640-50. doi: 10.1128/JVI.73.6.4640-4650.1999. J Virol. 1999. PMID: 10233923 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

618 results

Search Page